The microbiome, systemic immune function, and allotransplantation

Clinical Microbiology Reviews

Volumn 29, Issue 1, 2015, Pages 191-199

  Nellore, Anoma ^a,b   Fishman, Jay A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; RETINOIC ACID; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ALLOIMMUNITY; ALLOTRANSPLANTATION; ARTICLE; DYSBIOSIS; GRAFT REJECTION; HOMEOSTASIS; HUMAN; IMMUNE FUNCTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; ISCHEMIC PRECONDITIONING; LUNG TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROBIAL DIVERSITY; MICROBIOME; NATURAL KILLER CELL; NONHUMAN; PATHOLOGY; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; T CELL DEPLETION; TH1 CELL; TH17 CELL; VIRUS INFECTION; GRAFT RECIPIENT; MICROFLORA; ORGAN TRANSPLANTATION;

ADAPTIVE IMMUNITY; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; MICROBIOTA; ORGAN TRANSPLANTATION; REPERFUSION INJURY; TRANSPLANT RECIPIENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84949681424     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00063-15     Document Type: Article

References (104)

1. Maynard CL, Elson CO, Hatton RD, Weaver CT. 2012. Reciprocal interactions of the intestinal microbiota and immune system. Nature 489:231–241. http://dx.doi.org/10.1038/nature11551.
2. Belkaid Y, Hand TW. 2014. Role of the microbiota in immunity and inflammation. Cell 157:121–141. http://dx.doi.org/10.1016/j.cell.2014.03.011.
3. Surana NK, Kasper DL. 2014. Deciphering the tete-a-tete between the microbiota and the immune system. J Clin Invest 124:4197–4203. http: //dx.doi.org/10.1172/JCI72332.
4. Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, David H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, Guyer M. 2009. The NIH Human Microbiome Project. Genome Res 19:2317–2323. http://dx.doi.org/10.1101/gr.096651.109.
5. Li K, Bihan M, Yooseph S, Methe BA. 2012. Analyses of the microbial diversity across the human microbiome. PLoS One 7:e32118. http://dx.doi.org/10.1371/journal.pone.0032118.
6. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, Dubin KA, Socci ND, Viale A, Perales MA, Jenq RR, van den Brink MR, Pamer EG. 2012. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 55:905–914. http://dx.doi.org/10.1093/cid/cis580.
7. Huang YJ, Charlson ES, Collman RG, Colombini-Hatch S, Martinez FD, Senior RM. 2013. The role of the lung microbiome in health and disease. A National Heart, Lung, and Blood Institute workshop report. Am J Respir Crit Care Med 187:1382–1387. http://dx.doi.org/10.1164/rccm.201303-0488WS.
8. Human Microbiology Project Consortium. 2012. Structure, function and diversity of the healthy human microbiome. Nature 486:207–214. http://dx.doi.org/10.1038/nature11234.
9. Huffnagle GB, Noverr MC. 2013. The emerging world of the fungal microbiome. Trends Microbiol 21:334–341. http://dx.doi.org/10.1016/j.tim.2013.04.002.
10. Eckburg PB. 2005. Diversity of the human intestinal microbial flora. Science 308:1635–1638. http://dx.doi.org/10.1126/science.1110591.
11. Virgin HW. 2014. The virome in mammalian physiology and disease. Cell 157:142–150. http://dx.doi.org/10.1016/j.cell.2014.02.032.
12. Cox MJ, Cookson WO, Moffatt MF. 2013. Sequencing the human microbiome in health and disease. Hum Mol Genet 22:R88–R94. http: //dx.doi.org/10.1093/hmg/ddt398.
13. Krummey SM, Ford ML. 2012. Heterogeneity within T cell memory: implications for transplant tolerance. Front Immunol 3:36. http://dx.doi.org/10.3389/fimmu.2012.00036.
14. Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM, Wherry EJ, Onami T, Lanier JG, Kokko KE, Pearson TC, Ahmed R, Larsen CP. 2003. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111:1887–1895. http://dx.doi.org/10.1172/JCI200317477.
15. Pantenburg B, Heinzel F, Das L, Heeger PS, Valujskikh A. 2002. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol 169:3686–3693.
16. http: //dx.doi.org/10.4049/jimmunol.169.7.3686.
17. Johannessen I, Crawford DH. 1999. In vivo models for Epstein-Barr virus (EBV)-associated B cell lymphoproliferative disease (BLPD). Rev Med Virol 9:263–277.
18. Beus JM, Hashmi SS, Selvaraj SA, Duan D, Stempora LL, Monday SA, Cheeseman JA, Hamby KM, Speck SH, Larsen CP, Kirk AD, Kean LS. 2013. Heterologous immunity triggered by a single, latent virus in Mus musculus: combined costimulation- and adhesion-blockade decrease rejection. PLoS One 8:e71221. http://dx.doi.org/10.1371/journal.pone.0071221.
19. Yi JS, Cox MA, Zajac AJ. 2010. T-cell exhaustion: characteristics, causes and conversion. Immunology 129:474–481. http://dx.doi.org/10.1111/j.1365-2567.2010.03255.x.
20. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. 2007. Molecular signature of CD8_ T cell exhaustion during chronic viral infection. Immunity 27:670–684. http://dx.doi.org/10.1016/j.immuni.2007.09.006.
21. Ou R, Zhang M, Huang L, Moskophidis D. 2008. Control of virusspecific CD8_ T-cell exhaustion and immune-mediated pathology by E3 ubiquitin ligase Cbl-b during chronic viral infection. J Virol 82:3353–3368. http://dx.doi.org/10.1128/JVI.01350-07.
22. Wherry EJ. 2011. T cell exhaustion. Nat Immunol 12:492–499.
23. Amir AL, D’Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R, van der Hoorn MA, Kester MG, Doxiadis II, Falkenburg JH, Claas FH, Heemskerk MH. 2010. Allo-HLA reactivity of virusspecific memory T cells is common. Blood 115:3146–3157. http://dx.doi.org/10.1182/blood-2009-07-234906.
24. Schenk AD, Gorbacheva V, Rabant M, Fairchild RL, Valujskikh A. 2009. Effector functions of donor-reactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts. Am J Transplant 9:64–73. http://dx.doi.org/10.1111/j.1600-6143.2008.02460.x.
25. Gorres KL, Daigle D, Mohanram S, Miller G. 2014. Activation and repression of Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids. J Virol 88: 8028–8044. http://dx.doi.org/10.1128/JVI.00722-14.
26. Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL, Schwartz DA. 2003. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 168:628–632. http://dx.doi.org/10.1164/rccm.200303-447OC.
27. Palmer SM, Burch LH, Mir S, Smith SR, Kuo PC, Herczyk WF, Reinsmoen NL, Schwartz DA. 2006. Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clin Transplant 20:30–36. http://dx.doi.org/10.1111/j.1399-0012.2005.00436.x.
28. Kinnier CV, Martinu T, Gowdy KM, Nugent JL, Kelly FL, Palmer SM. 2011. Innate immune activation by the viral PAMP poly I:C potentiates pulmonary graft-versus-host disease after allogeneic hematopoietic cell transplant. Transpl Immunol 24:83–93. http://dx.doi.org/10.1016/j.trim.2010.11.004.
29. Garantziotis S, Palmer SM, Snyder LD, Ganous T, Chen BJ, Wang T, Cook DN, Schwartz DA. 2007. Alloimmune lung injury induced by local innate immune activation through inhaled lipopolysaccharide. Transplantation 84:1012–1019. http://dx.doi.org/10.1097/01.tp.0000286040.85007.89.
30. Alegre ML, Chen L, Wang T, Ahmed E, Wang CR, Chong A. 2009. Antagonistic effect of toll-like receptor signaling and bacterial infections on transplantation tolerance. Transplantation 87:S77–S79. http://dx.doi.org/10.1097/TP.0b013e3181a2b90f.
31. Wang T, Chen L, Ahmed E, Ma L, Yin D, Zhou P, Shen J, Xu H, Wang CR, Alegre ML, Chong AS. 2008. Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J Immunol 180:5991–5999. http://dx.doi.org/10.4049/jimmunol.180.9.5991.
32. Ahmed EB, Wang T, Daniels M, Alegre ML, Chong AS. 2011. IL-6 induced by Staphylococcus aureus infection prevents the induction of skin allograft acceptance in mice.AmJ Transplant 11:936–946. http://dx.doi.org/10.1111/j.1600-6143.2011.03476.x.
33. Chen L, Wang T, Zhou P, Ma L, Yin D, Shen J, Molinero L, Nozaki T, Phillips T, Uematsu S, Akira S, Wang CR, Fairchild RL, Alegre ML, Chong A. 2006. TLR engagement prevents transplantation tolerance. Am J Transplant 6:2282–2291. http://dx.doi.org/10.1111/j.1600-6143.2006.01489.x.
34. Han Lee ED, Kemball CC, Wang J, Dong Y, Stapler DC, Jr, Hamby KM, Gangappa S, Newell KA, Pearson TC, Lukacher AE, Larsen CP. 2006. A mouse model for polyomavirus-associated nephropathy of kidney transplants. Am J Transplant 6:913–922. http://dx.doi.org/10.1111/j.1600-6143.2006.01265.x.
35. Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D, Roggendorf M, von Weizsacker F, Blum HE, Thimme R. 2005. Intrahepatic CD8_T-cell failure during chronic hepatitis C virus infection. Hepatology 42:828–837. http://dx.doi.org/10.1002/hep.20856.
36. Nellore A, Fishman JA. 2011. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis 52:369–377. http: //dx.doi.org/10.1093/cid/ciq156.
37. Ciuffreda D, Codarri L, Buhler L, Vallotton L, Giostra E, Mentha G, Morel P, Pantaleo G, Pascual M. 2010. Hepatitis C virus infection after liver transplantation is associated with lower levels of activated CD4(_)CD25(_)CD45RO(_)IL-7ralpha(high) T cells. Liver Transpl 16:49–55. http://dx.doi.org/10.1002/lt.21959.
38. Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, Morales O, Chouzenoux S, Scatton O, Groux H, Auriault C, Calmus Y, Pancre V, Delhem N. 2009. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am J Transplant 9:2102–2112. http://dx.doi.org/10.1111/j.1600-6143.2009.02743.x.
39. Gredmark S, Soderberg-Naucler C. 2003. Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions. J Virol 77:10943–10956. http://dx.doi.org/10.1128/JVI.77.20.10943-10956.2003.
40. Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, Yousem SA, Close JM, Zeevi A, Duquesnoy RJ, Manzetti J, Keenan RJ, Armitage JM, Hardesty RL, Griffith BP. 1995. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 110:4–13. (Discussion 110:13–14.)
41. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. 1989. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261:3561–3566.
42. Dzabic M, Rahbar A, Yaiw KC, Naghibi M, Religa P, Fellstrom B, Larsson E, Soderberg-Naucler C. 2011. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 53:969–976. http://dx.doi.org/10.1093/cid/cir619.
43. Kumar D, Husain S, Chen MH, Moussa G, Himsworth D, Manuel O, Studer S, Pakstis D, McCurry K, Doucette K, Pilewski J, Janeczko R, Humar A. 2010. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 89:1028–1033. http://dx.doi.org/10.1097/TP.0b013e3181d05a71.
44. Koskinen P, Lemstrom K, Bruggeman C, Lautenschlager I, Hayry P. 1994. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis. Am J Pathol 144:41–50.
45. Craigen JL, Yong KL, Jordan NJ, MacCormac LP, Westwick J, Akbar AN, Grundy JE. 1997. Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology 92:138–145. http://dx.doi.org/10.1046/j.1365-2567.1997.00310.x.
46. Helantera I, Loginov R, Koskinen P, Tornroth T, Gronhagen-Riska C, Lautenschlager I. 2005. Persistent cytomegalovirus infection is associated with increased expression of TGF-beta1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts. Nephrol Dial Transplant 20:790–796. http://dx.doi.org/10.1093/ndt/gfh714.
47. Streblow DN, Kreklywich CN, Andoh T, Moses AV, Dumortier J, Smith PP, Defilippis V, Fruh K, Nelson JA, Orloff SL. 2008. The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants.AmJ Transplant 8:277–287. http://dx.doi.org/10.1111/j.1600-6143.2007.02062.x.
48. Potena L, Grigioni F, Magnani G, Lazzarotto T, Musuraca AC, Ortolani P, Coccolo F, Fallani F, Russo A, Branzi A. 2009. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 28:461–467. http://dx.doi.org/10.1016/j.healun.2009.02.009.
49. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC. 1999. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 340:1462–1470.
50. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. 2008. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 8:975–983. http://dx.doi.org/10.1111/j.1600-6143.2007.02133.x.
51. Fishman, JA. 2013. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Transplant 13(Suppl 3):1–8. http://dx.doi.org/10.1111/ajt.12002.
52. Mocarski ES, Jr. 2004. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 6:707–717. http://dx.doi.org/10.1111/j.1462-5822.2004.00425.x.
53. Couzi L, Pitard V, Moreau JF, Merville P, Dechanet-Merville J. 2015. Direct and indirect effects of cytomegalovirus-induced gammadelta T cells after kidney transplantation. Front Immunol 6:3. http://dx.doi.org/10.3389/fimmu.2015.00003.
54. Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ. 2008. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol 18:397–408. http://dx.doi.org/10.1016/j.semcancer.2008.10.008.
55. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. 2000. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A 97:1695–1700. http://dx.doi.org/10.1073/pnas.97.4.1695.
56. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT. 1995. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 182:477–486. http://dx.doi.org/10.1084/jem.182.2.477.
57. Graham JA, Wilkinson RA, Hirohashi T, Chase CM, Colvin RB, Madsen JC, Fishman JA, Russell PS. 2009. Viral infection induces de novo lesions of coronary allograft vasculopathy through a natural killer cell-dependent pathway. Am J Transplant 9:2479–2484. http://dx.doi.org/10.1111/j.1600-6143.2009.02801.x.
58. Floyd TL, Koehn BH, Kitchens WH, Robertson JM, Cheeseman JA, Stempora L, Larsen CP, Ford ML. 2011. Limiting the amount and duration of antigen exposure during priming increases memory T cell requirement for costimulation during recall. J Immunol 186:2033–2041. http://dx.doi.org/10.4049/jimmunol.1003015.
59. Diaz PI, Hong BY, Frias-Lopez J, Dupuy AK, Angeloni M, Abusleme L, Terzi E, Ioannidou E, Strausbaugh LD, Dongari-Bagtzoglou A. 2013. Transplantation-associated long-term immunosuppression promotes oral colonization by potentially opportunistic pathogens without impacting other members of the salivary bacteriome. Clin Vaccine Immunol 20:920–930. http://dx.doi.org/10.1128/CVI.00734-12.
60. Fricke WF, Maddox C, Song Y, Bromberg JS. 2014. Human microbiota characterization in the course of renal transplantation. Am J Transplant 14:416–427. http://dx.doi.org/10.1111/ajt.12588.
61. Lee JR, Muthukumar T, Dadhania D, Toussaint NC, Ling L, Pamer E, Suthanthiran M. 2014. Gut microbial community structure and complications after kidney transplantation: a pilot study. Transplantation 98:697–705. http://dx.doi.org/10.1097/TP.0000000000000370.
62. Hartman AL, Lough DM, Barupal DK, Fiehn O, Fishbein T, Zasloff M, Eisen JA. 2009. Human gut microbiome adopts an alternative state following small bowel transplantation. Proc Natl Acad SciUSA 106:17187–17192. http://dx.doi.org/10.1073/pnas.0904847106.
63. Wang F, Li Q, Wang C, Tang C, Li J. 2012. Dynamic alteration of the colonic microbiota in intestinal ischemia-reperfusion injury. PLoS One 7:e42027. http://dx.doi.org/10.1371/journal.pone.0042027.
64. Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, Ames S, Lerner S, Ebcioglu Z, Nair V, Dinavahi R, Sehgal V, Heeger P, Schroppel B, Murphy B. 2010. Immune reconstitution following rabbit antithymocyte globulin. AmJ Transplant 10:2132–2141. http://dx.doi.org/10.1111/j.1600-6143.2010.03210.x.
65. Ruggenenti P, Perico N, Gotti E, Cravedi P, D’Agati V, Gagliardini E, Abbate M, Gaspari F, Cattaneo D, Noris M, Casiraghi F, Todeschini M, Cugini D, Conti S, Remuzzi G. 2007. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 84:956–964. http://dx.doi.org/10.1097/01.tp.0000284808.28353.2c.
66. Tchao NK, Turka LA. 2012. Lymphodepletion and homeostatic proliferation: implications for transplantation. Am J Transplant 12:1079–1090. http://dx.doi.org/10.1111/j.1600-6143.2012.04008.x.
67. Kieper WC, Troy A, Burghardt JT, Ramsey C, Lee JY, Jiang HQ, Dummer W, Shen H, Cebra JJ, Surh CD. 2005. Recent immune status determines the source of antigens that drive homeostatic T cell expansion. J Immunol 174: 3158–3163. http://dx.doi.org/10.4049/jimmunol.174.6.3158.
68. Min B, Yamane H, Hu-Li J, Paul WE. 2005. Spontaneous and homeostatic proliferation of CD4 T cells are regulated by different mechanisms. J Immunol 174:6039–6044. http://dx.doi.org/10.4049/jimmunol.174.10.6039.
69. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. 2005. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122:107–118. http://dx.doi.org/10.1016/j.cell.2005.05.007.
70. An D, Oh SF, Olszak T, Neves JF, Avci FY, Erturk-Hasdemir D, Lu X, Zeissig S, Blumberg RS, Kasper DL. 2014. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell 156:123–133. http://dx.doi.org/10.1016/j.cell.2013.11.042.
71. Mazmanian SK, Round JL, Kasper DL. 2008. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620–625. http://dx.doi.org/10.1038/nature07008.
72. Goto Y, Panea C, Nakato G, Cebula A, Lee C, Diez MG, Laufer TM, Ignatowicz L, Ivanov II. 2014. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal th17 cell differentiation. Immunity 40:594–607. http://dx.doi.org/10.1016/j.immuni.2014.03.005.
73. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. 2009. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:485–498. http://dx.doi.org/10.1016/j.cell.2009.09.033.
74. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio CW, Santacruz N, Peterson DA, Stappenbeck TS, Hsieh CS. 2011. Peripheral education ofthe immune system by colonic commensal microbiota. Nature 478:250–254. http://dx.doi.org/10.1038/nature10434.
75. Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, Umetsu DT, Rudensky AY. 2012. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 482:395–399. http: //dx.doi.org/10.1038/nature10772.
76. Round JL, Mazmanian SK. 2010. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 107:12204–12209. http://dx.doi.org/10.1073/pnas.0909122107.
77. Geuking MB, Cahenzli J, Lawson MA, Ng DC, Slack E, Hapfelmeier S, McCoy KD, Macpherson AJ. 2011. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 34:794–806. http://dx.doi.org/10.1016/j.immuni.2011.03.021.
78. Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, Mazmanian SK. 2011. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332:974–977. http://dx.doi.org/10.1126/science.1206095.
79. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K. 2011. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331:337–341. http://dx.doi.org/10.1126/science.1198469.
80. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H. 2007. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317:256–260. http://dx.doi.org/10.1126/science.1145697.
81. Peck A, Mellins ED. 2010. Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 129:147–153. http://dx.doi.org/10.1111/j.1365-2567.2009.03189.x.
82. Rivas MN, Koh YT, Chen A, Nguyen A, Lee YH, Lawson G, Chatila TA. 2012. MyD88 is critically involved in immune tolerance breakdown at environmental interfaces of Foxp3-deficient mice. J Clin Invest 122: 1933–1947. http://dx.doi.org/10.1172/JCI40591.
83. Brandl K, Plitas G, Mihu CN, Ubeda C, Jia T, Fleisher M, Schnabl B, DeMatteo RP, Pamer EG. 2008. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 455:804–807. http://dx.doi.org/10.1038/nature07250.
84. Franchi L, Kamada N, Nakamura Y, Burberry A, Kuffa P, Suzuki S, Shaw MH, Kim YG, Nunez G. 2012. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol 13:449–456. http://dx.doi.org/10.1038/ni.2263.
85. Hill DA, Artis D. 2010. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol 28:623–667. http://dx.doi.org/10.1146/annurev-immunol-030409-101330.
86. Balmer ML, Slack E, de Gottardi A, Lawson MA, Hapfelmeier S, Miele L, Grieco A, Van Vlierberghe H, Fahrner R, Patuto N, Bernsmeier C, Ronchi F, Wyss M, Stroka D, Dickgreber N, Heim MH, McCoy KD, Macpherson AJ. 2014. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med 6:237ra266.
87. Kolios G, Valatas V, Kouroumalis E. 2006. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 12:7413–7420.
88. Arai M, Mochida S, Ohno A, Arai S, Fujiwara K. 1998. Selective bowel decontamination of recipients for prevention against liver injury following orthotopic liver transplantation: evaluation with rat models. Hepatology 27:123–127. http://dx.doi.org/10.1002/hep.510270120.
89. Corbitt N, Kimura S, Isse K, Specht S, Chedwick L, Rosborough BR, Lunz JG, Murase N, Yokota S, Demetris AJ. 2013. Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation.AmJ Pathol 182:180–191. http://dx.doi.org/10.1016/j.ajpath.2012.09.010.
90. Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, Gould K, Fisher AJ. 2008. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 85:771–774. http://dx.doi.org/10.1097/TP.0b013e31816651de.
91. Poroyko V, Semenyuk E, Xu Z-P, Sperling A, Alegre M-L, Chong A, Garrity E, White S, Bhorade S. 2014. Post-transplant dynamics of the pulmonary microbiota. AnnAmThorac Soc 11:S74. http://dx.doi.org/10.1513/AnnalsATS.201307-238MG.
92. Willner DL, Hugenholtz P, Yerkovich ST, Tan ME, Daly JN, Lachner N, Hopkins PM, Chambers DC. 2013. Reestablishment of recipientassociated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 187:640–647. http://dx.doi.org/10.1164/rccm.201209-1680OC.
93. Andrade-Oliveira V, Amano MT, Correa-Costa M, Castoldi A, Felizardo RJ, de Almeida DC, Bassi EJ, Moraes-Vieira PM, Hiyane MI, Rodas AC, Peron JP, Aguiar CF, Reis MA, Ribeiro WR, Valduga CJ, Curi R, Vinolo MA, Ferreira CM, Camara NO. 2015. Gut bacteria products prevent AKI induced by ischemia-reperfusion. JAmSoc Nephrol 26:1877–1888. http://dx.doi.org/10.1681/ASN.2014030288.
94. Ren Z, Cui G, Lu H, Chen X, Jiang J, Liu H, He Y, Ding S, Hu Z, Wang W, Zheng S. 2013. Liver ischemic preconditioning (IPC) improves intestinal microbiota following liver transplantation in rats through 16s rDNA-based analysis of microbial structure shift. PLoS One 8:e75950. http://dx.doi.org/10.1371/journal.pone.0075950.
95. Lukens JR, Gurung P, Vogel P, Johnson GR, Carter RA, McGoldrick DJ, Bandi SR, Calabrese CR, Walle LV, Lamkanfi M, Kanneganti TD. 2014. Dietary modulation of the microbiome affects autoinflammatory disease. Nature 516:246–249. http://dx.doi.org/10.1038/nature13788.
96. Oh PL, Martinez I, Sun Y, Walter J, Peterson DA, Mercer DF. 2012. Characterization of the ileal microbiota in rejecting and nonrejecting recipients of small bowel transplants. Am J Transplant 12:753–762. http://dx.doi.org/10.1111/j.1600-6143.2011.03860.x.
97. Lu H, He J, Wu Z, Xu W, Zhang H, Ye P, Yang J, Zhen S, Li L. 2013. Assessment of microbiome variation during the perioperative period in liver transplant patients: a retrospective analysis. Microb Ecol 65:781–791. http://dx.doi.org/10.1007/s00248-013-0211-6.
98. Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. 2014. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients.AmJ Transplant 14:477–480. http://dx.doi.org/10.1111/ajt.12577.
99. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile.NEngl J Med 368:407–415. http://dx.doi.org/10.1056/NEJMoa1205037.
100. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. 2015. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205–208. http://dx.doi.org/10.1038/nature13828.
101. Singh R, van Nood E, Nieuwdorp M, van Dam B, ten Berge IJ, Geerlings SE, Bemelman FJ. 2014. Donor feces infusion for eradication of extended spectrum beta-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect 20:O977–O978. http://dx.doi.org/10.1111/1469-0691.12683.
102. Stripling J, Kumar R, Baddley JW, Nellore A, Dixon P, Howard D, Ptacek T, Lefkowitz EJ, Tallaj JA, Benjamin WH, Jr, Morrow CD, Rodriguez JM. 2015. Loss of vancomycin-resistant Enterococcus fecal dominance in an organ transplant patient with Clostridium difficile colitis after fecal microbiota transplant. Open Forum Infect Dis 2:ofv078. http://dx.doi.org/10.1093/ofid/ofv078.
103. Lee JR, Muthukumar T, Dadhania D, Taur Y, Jenq RR, Toussaint NC, Ling L, Pamer E, Suthanthiran M. 2015. Gut microbiota and tacrolimus dosing in kidney transplantation. PLoS One 10:e0122399. http://dx.doi.org/10.1371/journal.pone.0122399.
104. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Berard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Dore J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L. 2013. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342:971–976. http://dx.doi.org/10.1126/science.1240537.